Literature DB >> 3261739

CD3+ CD8+ T cell lymphocytosis masking B cell leukaemia.

J L Smith1, D G Oscier, D G Haegert, D B Jones, M Howell, E Hodges, F K Stevenson, T J Hamblin.   

Abstract

A patient with CD3, CD8 positive lymphocytosis presented with features consistent with T cell chronic lymphocytic leukaemia/proliferations of large granular lymphocytes. The marrow and blood lymphoid populations (19.4 x 10(9)/l) contained more than 80% CD3 and CD8 positive cells with no evidence of a monotypic B cell population. A biopsy specimen of a vasculitic rash showed a diffuse infiltrate of CD3, CD8 positive cells into the upper dermis, consistent with T cell lymphocytic disease. After follow up for two years without treatment the blood lymphocyte count was 53 x 10(9)/l and was composed of cytologically small lymphocytes. A monoclonal SIg M D k lymphoid population (more than 90%) was demonstrable in sample blood and marrow aspirate. Gene rearrangement studies carried out on DNA extracted from peripheral blood lymphocytes at presentation and at two year follow up exhibited JH and Ck immunoglobulin gene rearrangement but no rearrangement of T cell receptor TcR gamma and beta genes. It is thought that this is the first well documented case of an aggressive CD8 positive lymphocytosis preceding, or in response to, an underlying B cell neoplasm.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261739      PMCID: PMC1141582          DOI: 10.1136/jcp.41.7.746

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  23 in total

1.  Characterization of a human B lymphocyte-specific antigen.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

2.  The distribution of a rabbit thymic antigen and membrane immunoglobulins in lymphoid tissue, with special reference to mucosal lymphocytes.

Authors:  O Rudzik; R L Clancy; D Y Perey; J Bienenstock; D P Singal
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

3.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

4.  Two monoclonal anti-human T lymphocyte antibodies have similar biologic effects and recognize the same cell surface antigen.

Authors:  G F Burns; A W Boyd; P C Beverley
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

Review 5.  Bleeding and thrombosis in the myeloproliferative disorders.

Authors:  A I Schafer
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

6.  Co-expression of T3 and surface immunoglobulin in neoplasms of 'early' B cells: a report of 2 cases.

Authors:  D G Haegert; J L Smith
Journal:  Eur J Haematol       Date:  1987-03       Impact factor: 2.997

7.  A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains.

Authors:  Y Yanagi; Y Yoshikai; K Leggett; S P Clark; I Aleksander; T W Mak
Journal:  Nature       Date:  1984 Mar 8-14       Impact factor: 49.962

8.  Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia.

Authors:  F Caligaris-Cappio; M Gobbi; M Bofill; G Janossy
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

9.  Immunoglobulin negative follicle centre cell lymphoma.

Authors:  E O Gregg; N Al-Saffar; D B Jones; D H Wright; F K Stevenson; J L Smith
Journal:  Br J Cancer       Date:  1984-12       Impact factor: 7.640

10.  Natural killer (NK) activity in peripheral blood lymphocytes of patients with benign and malignant breast disease.

Authors:  D White; D B Jones; T Cooke; N Kirkham
Journal:  Br J Cancer       Date:  1982-10       Impact factor: 7.640

View more
  1 in total

1.  Clonality of T cell and phenotypically undefined lymphoid neoplasms: the value of genotypic analyses.

Authors:  E Hodges; G N Stacey; W M Howell; D B Jones; J L Smith
Journal:  J Clin Pathol       Date:  1990-07       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.